ARVN
Arvinas, Inc.
FDA PDUFA Target Action Date
Friday, June 5, 2026
10 days away
Drug Information
- Drug Name
- Vepdegestrant (ARV-471) (CT.gov)
- Application Type
- NDA
- FDA Designations
- Fast Track
- Indication
- ESR1-mutated, ER+/HER2- advanced/metastatic breast cancer (post-endocrine therapy)
Filing Details
- Company
- Arvinas, Inc.
- Stock Ticker
- ARVN
- SEC CIK
- 0001655759
- Source
- Company IR →
What is a PDUFA Date?
A PDUFA (Prescription Drug User Fee Act) date is the FDA's target deadline to complete review of a drug application. The FDA aims to make an approval decision by this date.
- Standard Review: 10 months from filing acceptance
- Priority Review: 6 months from filing acceptance
- Possible Outcomes: Approval, Complete Response Letter (CRL), or extension
Track All FDA Decisions
View all upcoming PDUFA dates and AdCom meetings on our FDA Calendar.
View FDA Calendar →Data sourced from SEC EDGAR filings. Last updated: 2026-04-10. Report an issue